OFD Life Sciences Establishes Leadership Team and Welcomes CDMO Veteran Jim Miller to Board of Directors

Key leadership appointments fuel company's market growth in biopharma, medtech, and consumer health markets

ALBANY, Ore., March 24, 2025 /PRNewswire/ -- Oregon Freeze Dry ("OFD") Life Sciences announced today that it is building on OFD's 60 plus years of lyophilization expertise with multiple leadership appointments to its recently created Life Sciences division and the appointment of CDMO veteran Jim Miller to its board of directors.

"As the demand for CDMO knowledge and expertise grows, having a seasoned leader like Jim as a part of the OFD team positions us for strong growth and long-term success," said OFD CEO David Enloe. "His unparalleled strategic insights and experience give us a competitive edge that ensures we remain at the forefront of this expanding market."

Jim is a recognized expert in biopharmaceutical contract development and manufacturing organizations (CDMOs) with nearly 50 years of experience. During his career, he established and presided over the industry's principal online database on biopharmaceutical contract manufacturing intelligence, PharmSource Strategic Advantage.

Prior to founding PharmSource in 1996, Jim was vice president of sales and marketing at Circa Pharmaceuticals, Inc., a solid dose manufacturer. He was also president of St. Anthony Publishing, a provider of database information services for the healthcare industry. He was also a consultant in corporate strategy with the Boston Consulting Group. He holds an M.B.A. degree from the Stanford University Graduate School of Business.

Additionally, OFD announced key additions to its leadership team as it builds out the life sciences division.

• As previously announced in December 2024, David Enloe was appointed CEO. He brings a wealth of experience leading life science CDMOs such as Vivante GMP Solutions, Lonza, Althea, Ajinomoto Bio-Pharma Services, and Societal CDMO through build and growth phases.
• Walter Pebley, Ph.D., has been appointed Chief Scientific Officer. His work has been at the forefront of OFD's innovations in lyophilization and he has been solving problems and creating solutions for OFD customers for more than 40 years.
• Erica Raether has been appointed Chief People Officer. She brings more than 20 years of experience of increasing levels of responsibility in human capital leadership with biopharma CDMO and medical device companies, including Althea, Ajinomoto Bio-Pharma Services, and Societal CDMO.
• Shawna Monsoor has joined as a VP of Business Development. She brings nearly 20 years of commercial experience in life sciences, 13 of which have been spent as a commercial leader at many notable CDMOs such as Thermo Fisher Patheon, Ajinomoto, Abzena, Alcami, and Adare.
• Dan Peizer has joined the company as a VP of Business Development for OFD Life Sciences. He brings over 25 years of sales and marketing experience in life sciences across the animal health, consumer health, and pharma segments with Bayer and most recently with Catalent where he held leadership roles in both sales and marketing.

Founded in 1963, OFD is one of the largest and most technologically advanced freeze-dryer in North America. OFD has long been a leader in both global reach and the variety of uses to which it applies freeze drying technology.

About OFD Life Sciences

OFD Life Sciences is a division of Oregon Freeze Dry, one of the largest and most technologically advanced freeze-dryers in North America. OFD Life Sciences is a specialized CDMO focused on providing solutions to biopharma, consumer health, and animal health companies through its deep expertise in lyophilization. Featuring LyoLock™ bulk lyophilization services for API and ingredients, and patent pending LyoPastille® fast dissolve tablets, OFD Life Sciences preserves form, function, and stability while helping partners innovate to bring new and exciting products to market.

OFD Life Sciences Media Contact: 

Andrew Thompson-Young
Clarity Quest
[email protected]
615-784-3103

SOURCE OFD Life Sciences